GSK 598809
Alternative Names: GSK598809Latest Information Update: 01 Aug 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Behavioural disorder therapies
- Mechanism of Action Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eating disorders; Smoking withdrawal; Substance-related disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Eating-disorders in United Kingdom (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Smoking-withdrawal in Germany (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Smoking-withdrawal in USA (PO, Capsule)